633328-33-3

Basic information

• Product Name: 3-bromo-1H-pyrazolo[4,3-b]pyridine
• Synonyms: 3-bromo-1H-pyrazolo[4,3-b]pyridine;1H-Pyrazolo[4,3-b]pyridine,3-broMo-;3-Bromo-4-azaindazole
• CAS NO: 633328-33-3
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.03
• Product Categories: CHIRAL CHEMICALS;Building Blocks;Pyrazolo[x,x-y]pyridine;Heterocycle-Pyridine series
• Mol File: 633328-33-3.mol

Chemical Properties

• Boiling Point: 366.9 °C at 760 mmHg
• Flash Point: 175.7 °C
• Appearance: /
• Density: 1.894 g/cm³
• Vapor Pressure: 2.99E-05mmHg at 25°C
• Refractive Index: 1.745
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.76±0.40(Predicted)
• CAS DataBase Reference: 3-bromo-1H-pyrazolo[4,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-1H-pyrazolo[4,3-b]pyridine(633328-33-3)
• EPA Substance Registry System: 3-bromo-1H-pyrazolo[4,3-b]pyridine(633328-33-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 633328-33-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
3-Bromo-1H-pyrazolo[4,3-b]pyridine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Bromo-1H-pyrazolo[4,3-b]pyridine serves as a valuable building block for the creation of complex organic molecules. Its reactivity and structural features facilitate the synthesis of a wide range of chemical entities.
Used in Drug Development:
3-Bromo-1H-pyrazolo[4,3-b]pyridine is employed as a potential anti-cancer agent in drug development. Its ability to inhibit certain enzymes and its potential to target cancer cells make it a promising candidate for further research and development into effective cancer treatments.
Used in Enzyme Inhibition Studies:
In biological research, 3-Bromo-1H-pyrazolo[4,3-b]pyridine is used to study its potential as an enzyme inhibitor. Understanding its interactions with enzymes can provide insights into its mechanism of action and its possible use in treating various diseases.

InChI:InChI=1/C6H4BrN3/c7-6-5-4(9-10-6)2-1-3-8-5/h1-3H,(H,9,10)

Upstream product

• 272-52-6 1H-pyrazolo-[4,3-b]-pyridine 
• 31224-43-8 3-fluoropyridine-2-carbaldehyde 

Downstream Products

• 1357142-47-2 1-ethyl-3-[4-(pyridin-2-yloxy)phenyl]-1H-pyrazolo[4,3-b]pyridine 
• 1357142-84-7 4-(1-ethyl-1H-pyrazolo[4,3-b]pyridin-3-yl)phenol 
• 1330626-15-7 tert-butyl 3-((3-chlorophenyl)amino)-1H-pyrazolo[4,3-b]pyridine-1-carboxylate 
• 1041614-20-3 N-(3-chlorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine 
• 1561771-60-5 (3-bromo-4-fluoro-1H-indazol-1-yl)(2-chloro-6-(trifluoromethyl)phenyl)methanone 
• 1330624-42-4 N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine 
• 1432111-98-2 3-bromo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridine 
• 1432112-01-0 N-(4-chloro-3-methoxyphenyl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-amine 
• 1432112-28-1 2-chloro-N-(2-chloro-4-{[1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]amino}phenyl)-4-fluorobenzamide 
• 1432112-27-0 2-(2-chloro-4-{[1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]amino}phenyl)-1H-pyrrolo[3,4-c] pyridine-1,3(2H)-dione 
• 1432112-24-7 2-chloro-N⁴-[1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-yl]benzene-1,4-diamine 
• 1432135-75-5 N-(2-chloro-4-{[1-(4-methoxybenzyl)-1H-pyrazolo[4.3-b]pyridin-3-yl]amino}phenyl)acetamide 
• 1432112-20-3 N-(3,4-dichlorophenyl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-3-amine 

Relevant articles and documents

Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)

The efficacy of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclinical rodent models of Parkinson's disease has been established by a number of groups. Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506). We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a number of amide bioisosteres leading to the novel pyrazolo[4,3-b]pyridine head group. VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclinical safety species.

ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

Formula (I), and salts thereof, wherein R1, RA2, RA3 and RA4, are defined herein, which have properties for positive allosteric modulation of mGluR-4 receptor sites. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating Parkinson's disease and related disorders using the same.

ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

Disclosed are compounds of Formula (I), and salts thereof, wherein R1, RA2, RA3 and RA4, are defined herein, which have properties for positive allosteric modulation of mGluR-4 receptor sites. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating Parkinson's disease and related disorders using the same.

PYRAZOLOPYRIDINE, PYRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOUNDS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION

Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates -(CO)h-(NRa)j-(CRb=CRc)k-Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X-Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).